Health Technology · Biotechnology · NSE: ANTHEM · data 2026-10-09
Anthem Biosciences Limited
Health check: Average (5.9/10 on quality, valuation vs sector, growth and momentum).
Open full analysis — chart, results, balance sheet, red flags →Key figures
Price
₹862.3
Market cap
₹49,196 cr
P/E
85
P/B
—
ROE
21.7%
ROCE
26.0%
Debt / equity
0.02
Dividend yield
0.23%
1-year return
12.6%
52-week high
₹977.55
52-week low
₹579.15
Operating margin
32.7%
Growth
| Revenue (last 12 months) | ₹2,002 cr |
| Net profit (last 12 months) | ₹576 cr |
| Sales growth, 3 years (yearly) | 26.2% |
| Profit growth, 3 years (yearly) | 15.4% |
Similar companies
Rubicon Research Limited (RUBICON) · Akums Drugs and Pharmaceuticals Limited (AKUMS) · Fermenta Biotech Ltd (FERMENTA) · Fabtech Technologies Limited (FABTECH) · Haleos Labs Ltd. (HALEOSLABS)
The full analysis has the price chart, every quarterly result with YoY/QoQ growth, the balance sheet and cash flow with an accounting red-flag check, shareholding quarter by quarter with big investors, news, filings and bulk/block deals.
Open ANTHEM in NSE Scanner →